# Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia

> **NCT02144610** · PHASE3 · TERMINATED · sponsor: **AnGes USA, Inc.** · enrollment: 46 (actual)

## Conditions studied

- Critical Limb Ischemia

## Interventions

- **BIOLOGICAL:** HGF Plasmid (AMG0001)
- **BIOLOGICAL:** Matching Placebo

## Key facts

- **NCT ID:** NCT02144610
- **Lead sponsor:** AnGes USA, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-12
- **Primary completion:** 2016-11-28
- **Final completion:** 2016-11-28
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2019-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02144610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02144610, "Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02144610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*